Liu Na, Xie Zhanzhi, Li Hao, Wang Luqun
Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Sanofi China Investment Co., Ltd. Shanghai Branch, Shanghai 200000, P.R. China.
Oncol Lett. 2024 Apr 9;27(6):258. doi: 10.3892/ol.2024.14391. eCollection 2024 Jun.
Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal proliferation of abnormal plasma cells (PCs) in the bone marrow and recurrent cytogenetic abnormalities. The incidence of MM worldwide is on the rise. 1q21 has been found in ~30-40% of newly diagnosed MM (NDMM) patients.1q21 is associated with the pathophysiological mechanisms of disease progression and drug resistance in MM. In the present review, the pathogenesis and clinicopathological features of MM patients with 1q21 were studied, the key data of 1q21 on the prognosis of MM patients were summarized, and the clinical treatment significance of MM patients with 1q21 was clarified, in order to provide reference for clinicians to develop treatment strategies targeting 1q21.
多发性骨髓瘤（MM）是一种恶性肿瘤，其特征是骨髓中异常浆细胞（PC）的克隆性增殖和复发性细胞遗传学异常。全球MM的发病率正在上升。在约30%-40%的新诊断MM（NDMM）患者中发现了1q21。1q21与MM疾病进展和耐药的病理生理机制相关。在本综述中，研究了伴有1q21的MM患者的发病机制和临床病理特征，总结了1q21对MM患者预后的关键数据，并阐明了伴有1q21的MM患者的临床治疗意义，以便为临床医生制定针对1q21的治疗策略提供参考。
